Outcomes by Body Mass Index in Patients With B-Cell Precursor Acute Lymphoblastic Leukemia Treated with Inotuzumab Ozogamicin

Wendy Stock, Ryan D. Cassaday, Daniel J. DeAngelo, Anjali Advani, Nicola Gokbuget, Josep Ribera, Wei Jiang, Susana Pulido, Erik Vandendries, Nathan Braniff, Elias Jabbour, Hagop Kantarjian

Open source

DOI
10.1007/s11523-026-01253-w
Published
2026-09-16
Container
Targeted Oncology
Publisher
Springer Science and Business Media LLC
Open access
unknown

Credibility signals

uncertain Score 64/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

Cite this work

BibTeX

@article{allodium:10.1007/s11523-026-01253-w,
  title = {Outcomes by Body Mass Index in Patients With B-Cell Precursor Acute Lymphoblastic Leukemia Treated with Inotuzumab Ozogamicin},
  author = {Wendy Stock and Ryan D. Cassaday and Daniel J. DeAngelo and Anjali Advani and Nicola Gokbuget and Josep Ribera and Wei Jiang and Susana Pulido and Erik Vandendries and Nathan Braniff and Elias Jabbour and Hagop Kantarjian},
  year = {2026},
  journal = {Targeted Oncology},
  doi = {10.1007/s11523-026-01253-w},
  url = {https://doi.org/10.1007/s11523-026-01253-w}
}

RIS

TY  - JOUR
TI  - Outcomes by Body Mass Index in Patients With B-Cell Precursor Acute Lymphoblastic Leukemia Treated with Inotuzumab Ozogamicin
AU  - Wendy Stock
AU  - Ryan D. Cassaday
AU  - Daniel J. DeAngelo
AU  - Anjali Advani
AU  - Nicola Gokbuget
AU  - Josep Ribera
AU  - Wei Jiang
AU  - Susana Pulido
AU  - Erik Vandendries
AU  - Nathan Braniff
AU  - Elias Jabbour
AU  - Hagop Kantarjian
PY  - 2026
JO  - Targeted Oncology
DO  - 10.1007/s11523-026-01253-w
UR  - https://doi.org/10.1007/s11523-026-01253-w
ER  - 

APA

Stock, W., Cassaday, R. D., DeAngelo, D. J., Advani, A., Gokbuget, N., Ribera, J., Jiang, W., Pulido, S., Vandendries, E., Braniff, N., Jabbour, E., & Kantarjian, H. (2026). Outcomes by Body Mass Index in Patients With B-Cell Precursor Acute Lymphoblastic Leukemia Treated with Inotuzumab Ozogamicin. Targeted Oncology. https://doi.org/10.1007/s11523-026-01253-w

Source records